Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Context Therapeutics Inc.

    NASDAQ: CNTX · Real-Time Price · USD
    0.60
    -0.01 (-1.56%)
    At close: Jun 17, 2025, 3:21 PM

    Context Therapeutics Statistics

    Share Statistics

    Context Therapeutics has 89.7M shares outstanding. The number of shares has increased by 19.61% in one year.

    Shares Outstanding

    n/a
    		 89.7M

    Shares Change (YoY)

    n/a
    		 19.61%

    Shares Change (QoQ)

    n/a
    		 19.61%

    Owned by Institutions (%)

    n/a
    		 90.45%

    Shares Floating

    n/a
    		 57.81M

    Failed to Deliver (FTD) Shares

    n/a
    		 343

    FTD / Avg. Volume

    n/a
    		 0.15%

    Short Selling Information

    The latest short interest is 2.23M, so 2.49% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.23M

    Short % of Shares Out

    n/a
    		 2.49%

    Short % of Float

    n/a
    		 3.02%

    Short Ratio (days to cover)

    n/a
    		 8.68

    Valuation Ratios

    The PE ratio is -2.3 and the forward PE ratio is -1.81. Context Therapeutics's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -2.3

    Forward PE

    n/a
    		 -1.81

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.7

    PB Ratio

    n/a
    		 0.64

    P/FCF Ratio

    n/a
    		 -2.09

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Context Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 35.62, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 35.62

    Quick Ratio

    n/a
    		 35.62

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,227,083.33

    Employee Count

    n/a
    		 12

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -68.56% in the last 52 weeks. The beta is 1.86, so Context Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.86

    52-Week Price Change

    n/a
    		 -68.56%

    50-Day Moving Average

    n/a
    		 0.74

    200-Day Moving Average

    n/a
    		 1.26

    Relative Strength Index (RSI)

    n/a
    		 41.89

    Average Volume (20 Days)

    n/a
    		 234,553

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -29.92M

    Net Income

    n/a
    		 -26.73M

    EBITDA

    n/a
    		 -26.67M

    EBIT

    n/a
    		 -26.73M

    Earnings Per Share (EPS)

    n/a
    		 -0.46
    Full Income Statement

    Balance Sheet

    The company has 94.43M in cash and 219.38K in debt, giving a net cash position of 94.21M.

    Cash & Cash Equivalents

    n/a
    		 94.43M

    Total Debt

    n/a
    		 219.38K

    Net Cash

    n/a
    		 94.21M

    Retained Earnings

    n/a
    		 -94.78M

    Total Assets

    n/a
    		 92.97M

    Working Capital

    n/a
    		 90.83M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -14.56M and capital expenditures -14.76M, giving a free cash flow of -29.31M.

    Operating Cash Flow

    n/a
    		 -14.56M

    Capital Expenditures

    n/a
    		 -14.76M

    Free Cash Flow

    n/a
    		 -29.31M

    FCF Per Share

    n/a
    		 -0.5
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CNTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CNTX is $5, which is 719.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $5

    Price Target Difference

    n/a
    		 719.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 16

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist